Related Experiment Video

Updated: Nov 3, 2025

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.3K

Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues

Shaimaa El-Fayoumi1,2, Rehab Mansour1,3, Amr Mahmoud1,4

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.

Pharmacology
|June 3, 2021
PubMed
Abstract

Insights

Pioglitazone enhances insulin sensitivity by increasing beta-arrestin2 signaling in key tissues like the liver and muscle. This study reveals a new mechanism for this antidiabetic drug.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Pioglitazone is an oral antidiabetic agent belonging to the thiazolidinedione class.
  • Insulin resistance is a hallmark of type 2 diabetes, affecting major metabolic tissues.
  • Beta-arrestin2 signaling plays a role in cellular responses to insulin.

Purpose of the Study:

  • To investigate the impact of pioglitazone on beta-arrestin2 signaling.
  • To determine if pioglitazone's insulin-sensitizing effects involve beta-arrestin2.
  • To examine these effects in classical insulin target tissues.

Main Methods:

  • Mice were divided into three groups: standard chow, high-fructose, high-fat diet (HFrHFD), and HFrHFD with pioglitazone treatment.
  • Pioglitazone was administered orally for the final four weeks of the HFrHFD feeding period.
  • Insulin sensitivity, beta-arrestin2 levels, and downstream signaling molecules were assessed.

Main Results:

  • Pioglitazone treatment significantly improved insulin sensitivity, indicated by a reduced insulin resistance index.
  • Beta-arrestin2 levels and signaling were significantly increased in adipose tissue, liver, and skeletal muscle of treated mice.
  • Key signaling molecules, including phosphatidylinositol 4,5 bisphosphate and phosphorylated Akt, were elevated, while diacylglycerol was reduced.

Conclusions:

  • This study identifies a novel mechanism for pioglitazone's action in enhancing insulin sensitivity.
  • Pioglitazone's beneficial effects are linked to increased beta-arrestin2 signaling in insulin target tissues.
  • The findings contribute to understanding pioglitazone's role in metabolic regulation.
Keywords:
DiacylglycerolFatFructoseInsulin resistancePioglitazoneβ-arrestin2

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.1K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.9K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
315
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
380
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
509
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
342
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
345
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.8K